Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2007

View Archived Issues

Novel metabolic drugs reported in recent patent literature

Recent patents disclose novel therapeutic agents for gastrointestinal disorders

Liposomal curcumin shows efficacy against head and neck cancer cells

ShK5(L5) delays extravasation and reduces motility of effector memory T-cells

PsychoGenics and Amylin establish Psylin Neurosciences

Simvastatin enhances cognition by Abeta-independent mechanism in mice

Phase III program under way for NM-100060 in onychomycosis

NCI studies RM-1812 as chemopreventive agent

Novel STAT6 inhibitor for allergic disorders reported by Astellas

EpiVax tularemia vaccine candidate confers protective immunity in mice

Osprey secures financing to advance OPL-CCL2-LPM into clinic

End-of-phase II meeting for Pollinex Quattro Ragweed

BioXell exercises option to Roche compound

Ligand restructures

AstraZeneca to acquire Arrow Therapeutics

NX-1207 attracts licensing offers

SGX selects MET tyrosine kinase inhibitor development candidate

U.S. orphan drug status granted for Aastrom's TRCs in dilated cardiomyopathy

Enrollment complete in phase IIb diabetes study of CS-917

Japanese phase I testing of Hematide triggers milestone payment

Alnylam preclinical data support further exploration of siRNAs

JNJ-26146900: novel selective androgen receptor modulator effective in rodent prostate cancer models

AGI reports initial phase II results in functional diarrhea, functional dyspepsia

Results of first paclitaxel-eluting stent study in peripheral arterial disease

Improved pharmacokinetics of disodium salt of CH-1504

Approvable letter for new Arixtra indications

Celecox approved in Japan